[Treatment of cervical carcinoma in mice by injecting monoclonal antibody of epidermal growth factor receptor into solid tumor].
OBJECTIVE
To observe the effect of treating cervical carcinoma in mice by injecting monoclonal antibody of epidermal growth factor receptor (EGFR-McAb) into solid tumor.


METHODS
Six hundred and fifteen strain mice bearing U14 cervical cancer cell were subcutaneously injected with EGFR-McAb in Group A and B. The mice in control Group A and B were injected with 0.9% sodium chloride instead of EGFR-McAb. The volume of the tumor in Group A as measured for 2 weeks consecutively. The survival time of the mice both in Group A and in control Group A were observed. The mice in Group B were killed in the 4th, 7th, 10th, 14th, 16th, and 17th days. Tissue section of the tumor as stained immunohistochemically for CD31. Active areas of angiogenesis chosen under microscope and average microvessels counted per field(40x) were taken as intratumor microvessel density(IMD).


RESULTS
(1) The mean survival time in Group A was 42.8 day while in control Group A it was 28.3 day. (2) The tumor growth inhibitory rate in Group A in the 4th, 7th, 10th, and 14th days was 13%, 42%, 83%, and 84%, respectively, and in the 7th, 10th and 14th days there was a significant difference(P < 0.05). (3) The Group B was 15.6 +/- 4.0, while in control Group B it was 31.1 +/- 14.6. The average IMD in the Group B was lower than that in the control Group B.


CONCLUSIONS
An effective treatment to cervical cancer in mice can be made with EGFR-McAb. It is suggested that EGFR-McAb may be a target for treating cervical cancer.
Nie
M F
MF
Department of Obstetrics and Gynecology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Liu
F Y
FY
Tao
G S
GS
D000287:Administration, Topical; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000276:immunology*; D005260:Female; D051379:Mice; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000098:blood supply / Q000628:therapy*
D000911:Antibodies, Monoclonal; D066246:ErbB Receptors